Journal of wound care最新文献

{"title":"Tracing harm, driving change: how frontline risks inform systemic quality and safety policies.","authors":"Valter R Fonseca, Damir Ivankovic, Nurshaim Tilenbaeva, Christos Triantafyllou, Joao Breda","doi":"10.12968/jowc.2025.0316","DOIUrl":"https://doi.org/10.12968/jowc.2025.0316","url":null,"abstract":"","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 9","pages":"676-677"},"PeriodicalIF":1.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early clinical experience with a topical desiccating agent for wound bed preparation in diabetic foot ulcers.","authors":"Johannes P Snels, Alberto Cogo, Rachele Reitano, Chiara Grigolo, Bertus J Quint, Carlo A Bignozzi","doi":"10.12968/jowc.2025.0240","DOIUrl":"https://doi.org/10.12968/jowc.2025.0240","url":null,"abstract":"<p><p>Diabetic foot ulcers (DFUs) are a major complication of diabetes, often requiring effective wound bed preparation for healing. This retrospective case series assessed a novel topical desiccating agent (TDA) used under a compassionate-use protocol approved by the institutional ethics board. A total of 67 patients with hard-to-heal (chronic) DFUs treated between 2020 and 2023 were included. Granulation was achieved in 88.1% of patients (mean time: 44.3 days), and 85.1% reached complete re-epithelialisation. No adverse events were reported. TDA was well tolerated and showed promising clinical outcomes in a high-risk patient population, supporting further evaluation in prospective studies.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 9","pages":"704-706"},"PeriodicalIF":1.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential cost savings of a wound bed-conforming silicone foam dressing with 3DFit Technology compared with standard of care.","authors":"Caroline Dowsett, Julie Beck Christoffersen, Mette Irene Agerkvist Hansen, Paddy Markey","doi":"10.12968/jowc.2025.0291","DOIUrl":"https://doi.org/10.12968/jowc.2025.0291","url":null,"abstract":"<p><strong>Objective: </strong>The increasing prevalence of chronic wounds, particularly venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs), presents significant clinical and economic challenges within the National Health Service in the UK. This study was designed to evaluate the financial impact of replacing the standard of care (SoC), two-dressing regimen with a single silicone foam dressing with 3DFit Technology, Biatain Silicone (Coloplast, UK), in the treatment of these wounds in the community setting in the UK.</p><p><strong>Method: </strong>A budget impact model was developed to estimate the potential cost savings of a progressive transition from SoC to the single silicone foam dressing with 3DFit Technology over a five-year horizon. The target group was estimated based on current population data, an estimation of the population with VLUs and DFUs, and finally the wound eligibility criteria for using Biatain Silicone. The model was created from a payer perspective. A conservative approach was taken in estimating the target population, annual growth rate, unit cost and uptake rate.</p><p><strong>Results: </strong>The model indicated potential cost savings of £5.1 million by switching from the two-dressing regimen to the single silicone foam dressing with 3DFit Technology for patients with VLUs and DFUs over a five-year period.</p><p><strong>Conclusion: </strong>This study indicated potential cost savings by transitioning from SoC to a single silicone foam dressing with 3DFit Technology in the treatment of patients with VLUs and DFUs without compromising the clinical outcomes in wound management.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 9","pages":"724-730"},"PeriodicalIF":1.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pressure injuries in patients receiving extracorporeal membrane oxygenation: a tertiary centre experience.","authors":"Halide Oğuş, A Ece Altınay, Fatih Yiğit, Ayhan Güneş, Yeliz Karacı, Seda Karasakal, Merve Karanis Taştan, Ceyda Canbey Baydilli, Şirin Menekşe, Mehmet Kaan Kırali","doi":"10.12968/jowc.2023.0218","DOIUrl":"10.12968/jowc.2023.0218","url":null,"abstract":"<p><strong>Objective: </strong>Pressure injuries (PIs) are common in patients receiving intensive care and extracorporeal membrane oxygenation (ECMO). This study assessed the incidence and risk factors of PIs in patients receiving ECMO for COVID-19-associated acute respiratory distress syndrome (ARDS).</p><p><strong>Method: </strong>Patients who were admitted to the intensive care unit (ICU) with severe COVID-19-associated ARDS and received veno-venous ECMO between April 2020 and January 2022 were evaluated. All patients were monitored, evaluated and managed according to the <i>Prevention and treatment of pressure ulcers: clinical practice guideline 2019</i>. The risk for PI was evaluated using the Braden scale. Staging of PIs was made according to the National Pressure Injury Advisory Panel guidelines.</p><p><strong>Results: </strong>A total of 78 patients (median age 45 years) received ICU care and ECMO support. Of these, 75 patients were transferred to the ICU while on ECMO support; 24/78 (30.8%) patients already had PIs. New PIs developed in 24 patients (24/54, 44.4%) during prolonged periods of ECMO (median 48.5 days). The new PIs were mainly stage 2 (55%). The median time to new PI development during ECMO was 21 (range 4-60) days. The mortality rate was 32/54 (59.3%). In multivariable analysis, age (odds ratio (OR): 1.103, 95% confidence interval (CI): 1.022, 1.191; p=0.027) and ECMO duration (OR: 1.048, 95% CI: 1.016, 1.081; p=0.003) were independent predictors of PI development.</p><p><strong>Conclusion: </strong>Strict compliance with the clinical practice guidelines for PIs by a dedicated ICU team may considerably reduce the incidence of PIs among patients receiving ECMO for prolonged periods.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"571-578"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empowering tomorrow's innovators: the significance of student-led research.","authors":"Windy Cole","doi":"10.12968/jowc.2025.0305","DOIUrl":"10.12968/jowc.2025.0305","url":null,"abstract":"","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"541"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of single-use negative pressure wound therapy on healthcare use: US analysis of a large claims database.","authors":"Ravi K Bashyal, Richard Searle, Leo M Nherera, Adam Wright","doi":"10.12968/jowc.2024.0339","DOIUrl":"10.12968/jowc.2024.0339","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effect of two single-use negative pressure wound therapy (sNPWT) devices on healthcare resource use (HCRU) and surgical site complications (SSCs) after orthopaedic and cardiovascular surgery.</p><p><strong>Method: </strong>Patient data were collected from the US-based Premier PINC AI Healthcare Database between January 2017 and June 2022. Adult patients upon whom the -80mmHg or -125mmHg sNPWT device was used within predefined orthopaedic and cardiovascular surgical categories were included. The HCRU endpoints measured were index encounter length of stay (LoS), and cost at index encounter and at 30 and 90 days post-surgery. Clinical endpoints were also assessed.</p><p><strong>Results: </strong>The mean index encounter LoS, and mean cost at index admission and at 30 and 90 days post-surgery were all significantly lower when the -80mmHg device was used, compared with the -125mmHg device, across orthopaedic and cardiovascular wounds (all p<0.0001). The odds ratio (OR) for dehiscence (30 days) was significantly lower when the -80mmHg device was used versus the -125mmHg device in orthopaedic (OR: 0.361; p≤0.05) and cardiovascular (OR: 0.422; p≤0.01) wounds. Differences between the devices were not found in superficial and deep surgical site infections or seroma for either orthopaedic or cardiovascular incisions (p>0.05).</p><p><strong>Conclusion: </strong>The -80mmHg device was associated with significantly lower HCRU and likelihood of dehiscence after orthopaedic and cardiovascular surgery versus the -125mmHg device and there were no differences in other SSCs.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"555-562"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Botulinum neurotoxin A for treatment of pain in lower extremity ulcers: an exploratory study.","authors":"Lubna Sabah, Ewa Anna Burian, Magnus S Ågren, Klaus Kirketerp-Møller, Simon Francis Thomsen, Finn Borgbjerg Moltke","doi":"10.12968/jowc.2024.0285","DOIUrl":"10.12968/jowc.2024.0285","url":null,"abstract":"<p><strong>Objective: </strong>Pain in patients with leg ulcers is common and there is a need for effective treatments. The analgesic effects of botulinum neurotoxin A (BTX-A) have been well-documented and this exploratory study primarily investigated its analgesic effect in patients with leg ulcers.</p><p><strong>Method: </strong>In this prospective, investigator-initiated, open-label, clinical trial, patients with leg and foot ulcers dominated by neuropathic wound pain were enrolled consecutively and treated with perilesional injections of BTX-A on day 0 (D0). The patients were followed-up on D21, D60 and D90.</p><p><strong>Results: </strong>A total of 10 patients with leg and foot ulcers were enrolled in this study (≥30mm on a visual analogue scale (VAS) for pain from 0-100mm)-seven with venous leg ulcers and three with inflammatory ulcers. After starting treatment with BTX-A, pain was reduced by ≥20mm on the VAS at D21 (pre-defined endpoint) in seven (70%) patients (p<0.05). Neuropathic pain scores (Douleur Neuropathique 4 questionnaire) were significantly (p<0.05) reduced at all follow-up visits, while wellbeing scores (World Health Organization-5) increased significantly (p<0.05) after BTX-A injection. Percentage reduction of wound area was significant from D60 onwards. The wound fluid levels of interleukin-1β and the neuropeptide calcitonin gene-related peptide resembled the wound healing course. BTX-A was well-tolerated with no drug-related severe adverse events.</p><p><strong>Conclusion: </strong>The findings of this study demonstrated that BTX-A holds potential for wound pain management and justify the need for more rigorous clinical investigations.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"608-615"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulnamin as an adjunct to standard of care in hard-to-heal venous leg ulcers: clinical effectiveness and cost modelling.","authors":"Abida Arif, Ioan Humphreys, Steven Jeffery","doi":"10.12968/jowc.2025.0056","DOIUrl":"10.12968/jowc.2025.0056","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the rate at which Vulnamin (Professional Dietetics S.p.A., Italy), a combination of hyaluronic acid and amino acids, heals hard-to-heal venous leg ulcers (VLUs) by measuring percentage area reduction (PAR), wound bed condition, slough presence, infection, oedema, pain and general ulcer health. It also aimed to model the cost-effectiveness of the product as an adjunct when used alongside standard of care (SoC) of leg ulcers.</p><p><strong>Method: </strong>Patients with hard-to-heal VLUs were treated with the evaluated adjunct product for up to six weeks. Formulations were prescribed based on ulcer size, depth and levels of slough. Treatments involved both cream and powder formulations as adjunct to SoC. Wound size was measured and photographic evidence was documented throughout. The costing analysis was based on resource utilisation and clinical effectiveness data reported from the service evaluation. The total cost of the evaluated adjunct product over a four week period was calculated to be £813.39.</p><p><strong>Results: </strong>A total of 20 patients took part in the evaluation. Wound healing spanned 63 days, with an average size at baseline of 6.7cm². By day 7, the wound area had reduced to 5.36cm², by day 14 to 4.93cm², by day 21 to 4.42cm², and by day 35 to 3.4cm². The overall PAR reached 76.26% by day 63, showing consistent improvement. The cumulative costs associated with the evaluated adjunct product over four weeks were £2621.64, compared with the cumulative costs of SoC alone over four weeks of £1323.28. However, if the Vulnamin adjunct costs halt at four weeks, but the costs in the SoC group continue to accumulate, the cost at 111 days (16 weeks and 6 days) for a hard-to-heal wound would be £2622.93, compared to £2621.64 for the Vulnamin adjunct costs. This is the point that the healing cost of the evaluated adjunct product starts to become cost-saving to the UK's National Health Service.</p><p><strong>Conclusion: </strong>In this study, Vulnamin showed promise in accelerating VLU healing. However, given the small sample size, and given the variability in ulcer characteristics and comorbidities, this underscores the need for further research with a larger, more diverse patient populations to confirm and extend these results. The analysis indicates positive cost-saving results based on the 20 patients within the study. Further research is needed to validate the potential of Vulnamin use in wound care.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"623-630"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute microcirculatory effects of remote ischaemic conditioning in hard-to-heal wounds.","authors":"Julia Lucius, Mascha Groß, Sophie Schleusser, Henriette Deichmann, Marco Horn, Raphael R Tasar, Jan-Oluf Jensen, Felix H Stang, Peter Mailänder, Tobias Kisch","doi":"10.12968/jowc.2023.0134","DOIUrl":"10.12968/jowc.2023.0134","url":null,"abstract":"<p><strong>Objective: </strong>Remote ischaemic conditioning (RIC) is known to have a positive impact on heart muscle cells, kidney and liver cells. RIC improves microcirculation in healthy skin. Microcirculation is a crucial factor in wound healing. This study examined the microcirculatory effects of RIC in hard-to-heal (chronic) wounds based on the hypothesis that RIC improves cutaneous microcirculation in hard-to-heal wounds.</p><p><strong>Method: </strong>Patients with hard-to-heal wounds (>3 weeks) participated in the study. RIC comprised three ischaemia cycles (five-minute inflation of blood pressure cuff to 200mmHg), each followed by a 10-minute reperfusion phase on a healthy upper limb. After the third and final ischaemia cycle, a reperfusion of 20 minutes ensued. Microcirculation was continuously recorded through a combined laser Doppler and white light spectrometry.</p><p><strong>Results: </strong>The cohort comprised 20 patients. In hard-to-heal wounds, oxygen saturation in a 6-8mm tissue depth was increased by a maximum of 11.2% (percentage change from baseline; p<0.02) and capillary blood flow was increased by a maximum of 47.7% (p<0.0001). There was no significant change of the postcapillary venous filling pressure.</p><p><strong>Conclusion: </strong>The results of this study showed that RIC enhanced microcirculation in hard-to-heal wounds by elevating capillary blood flow and oxygen saturation.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"631-636"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of chronic wounds with cold plasma: a randomised, single-blind, placebo-controlled clinical study.","authors":"Robert Strohal, Martina Mittlböck, Lisa Gebhardt, Gilbert Hämmerle","doi":"10.12968/jowc.2025.0207","DOIUrl":"10.12968/jowc.2025.0207","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the wound healing properties of cold atmospheric plasma (CAP) in patients with chronic wounds.</p><p><strong>Method: </strong>This was a prospective, multicentre, two-arm, randomised, single-blind clinical study which compared the wound healing treatment of CAP with placebo, both of which were combined with best practice wound care.</p><p><strong>Results: </strong>The study cohort consisted of 70 patients: 35 in the CAP group and 35 in the placebo group. There was a statistically significant (p<0.0001) reduction in the wound area at the end of the study, and faster wound healing, with the use of CAP compared with a placebo device.</p><p><strong>Conclusion: </strong>The results of this study showed that without requiring adjunctive therapies, the CAP device represents a safe, well-tolerated, and highly effective therapeutic option for wounds in that it promotes their rapid healing.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 8","pages":"542-554"},"PeriodicalIF":1.7,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}